Please login to the form below

Not currently logged in
Email:
Password:

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

China’s Innovent to start US trials of anti-CD47 cancer drug

China’s Innovent to start US trials of anti-CD47 cancer drug

Innovent reckons IB-188 has stronger receptor blocking ability than other investigational drugs against CD47, and says it intends to start several clinical trials across multiple cancers, including non-Hodgkin's ... lymphoma and ovarian cancer.

Latest news

  • It’s a no for Yescarta, says NICE on heels of EU approval It’s a no for Yescarta, says NICE on heels of EU approval

    It’s disappointing that patients with non-Hodgkin lymphoma who have exhausted all other treatment options will not be able to access CAR T cell therapy – a brand new type of ... Cell therapy is a new and advanced technology and, as NICE have

  • FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

    FDA clears Kyowa Kirin’ s skin lymphoma therapy Poteligeo. Becomes the first drug approved to treat Sézary syndrome. ... Both MF and SS are a rare form of non-Hodgkin’s lymphoma (NHL) collectively known as cutaneous T-cell lymphomas (CTCL), and are

  • Celgene’s Revlimid gets a win in late-stage lymphoma Celgene’s Revlimid gets a win in late-stage lymphoma

    Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment for patients with non-Hodgkin’s lymphoma who have relapsed or ... Indolent non-Hodgkin lymphomas, such as FL and MZL, are diseases of

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s

  • Another R&D flop for Incyte, but Jakafi keeps delivering Another R&D flop for Incyte, but Jakafi keeps delivering

    Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in

More from news
Approximately 15 fully matching, plus 115 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics